You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: VICAL, INC. Topic: N/A
DESCRIPTION (provided by applicant): Vical Inc. seeks SBIR Phase II funding to develop and produce a licensable prophylactic anthrax vaccine. This project will move on an accelerated but realistic timeline with plans for human clinical trials to begin in September 2003. Although many candidate vaccines are being studied for anthrax prevention or post-exposure prophylaxis, the Vical approach has ...STTR Phase II 2003 Department of Health and Human ServicesNational Institutes of Health
SBC: BIOSENSICS LLC Topic: NIA
With a Phase I/II STTR grant award from NIA, BioSensics in collaboration with Baylor College of Medicine (BCM) successfully developed and commercialized an advanced physical activity monitoring system (PAMSys™) for older adults. PAMSys enables continuous remote monitoring of physical activity, fall risk, and fall incidents. The fall detection technology of PAMSys has become the gold standard in ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: CEPHEID Topic: N/A
DESCRIPTION (provided by applicant): Cepheid Inc and the New Jersey Medical School have developed an assay system that integrates sample processing and real-time PCR diagnosis into a single, hands free process. During the successful completion of a phase I STTR application we demonstrated that this system simultaneously detect the presence of Mycobacterium tuberculosis (TB) and diagnose rifampin r ...STTR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
SBC: BIOLOGICAL ANTI-INFECTIVE MEDICINES, LLC Topic: NIAID
DESCRIPTIONprovided by applicantNational surveillance data confirm thatof Abaumannii isolates from US intensive care units are extreme drug resistanceXDRfar higher than other pathogensAt leastandcases of XDR Abaumannii infections occur annually in the US and globallyin developed countriesrespectivelyThese infections result inanddeaths and excess healthcare costs of $million and $million in the US ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: EIGER GROUP INTERNATIONAL, INC. Topic: NIAID
DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) is an important worldwide cause of liver disease. Current standard of care (SOC) agents are inadequate for most patients, and new virus-specific drugs are urgently needed. Our long-term objective is to bring a new class of anti-HCV drugs to the clinic. We discovered that the HCV NS4B protein specifically binds a key segment of the HCV RN ...STTR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
SBC: VESTAN INC Topic: NCI
DESCRIPTION (provided by applicant): In this Phase II STTR project, Vestan Medical Imaging, Inc. will complete the development and clinical evaluation of its proprietary formulation of a fluorescent drug and new medical devices for Sentinel Lymph Node (SLN) biopsy for the surgical treatment of melanoma and breast cancer. Vestan will partner with the University of Utah Huntsman Cancer Institute (HC ...STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
SBC: Integrated Biotherapeutics, Inc. Topic: NIAID
Project Summary Bacillus anthracis (Ba) is a Gram-positive spore forming bacterium that is listed as an agent of highest concern (Category A) by NIAID and CDC. Ba is easy to grow, and its spores can be formulated into highly stable powder form and disseminated as aerosol or used to contaminate food or water. In 2001, letters laced with powdered anthrax spores were mailed to several US politicians. ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: SILVER LAKE RESEARCH CORPORATION Topic: NIAID
PROJECT SUMMARY ABSTRACT This proposal describes Phase II of the development of a rapid immunoassay test kit for the determination oflactam antibiotic resistanceto be used as a point of care diagnostic test for urinary tract infectionsTodayantibiotics for UTI are prescribed empiricallywith no diagnostics available to clinicians to avoid treating resistant infections with the very drug to which the ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: NeuroSigma, Inc. Topic: 101
DESCRIPTIONprovided by applicantThe purpose of this project is to develop an improvedminimally invasive treatment for intracranial aneurysmsIntracranial aneurysms are spherical outpouchings of blood vessels in the head that result from weakness in the vessel wallUnruptured aneurysms are present in approximatelyof the general populationand rupture can be devastating with a high morbidity and mortal ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: Aridis Pharmaceuticals, Inc. Topic: NIAID
DESCRIPTION (provided by applicant): Over the past two decades, the number of new antimicrobials being developed has experienced a greater than 60% decline, while the number of antibiotic resistant microorganisms has been steadily increasing. Only one newantibacterial drug with a novel mechanism of action (linezolid) has been introduced during this period making the long term outlook for sustained ...STTR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health